These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Exploiting the interaction between Grp94 and aggregated myocilin to treat glaucoma. Stothert AR; Suntharalingam A; Huard DJ; Fontaine SN; Crowley VM; Mishra S; Blagg BS; Lieberman RL; Dickey CA Hum Mol Genet; 2014 Dec; 23(24):6470-80. PubMed ID: 25027323 [TBL] [Abstract][Full Text] [Related]
8. Synthesis and evaluation of radamide analogues, a chimera of radicicol and geldanamycin. Hadden MK; Blagg BS J Org Chem; 2009 Jul; 74(13):4697-704. PubMed ID: 19492825 [TBL] [Abstract][Full Text] [Related]
10. Different Grp94 components interact transiently with the myocilin olfactomedin domain in vitro to enhance or retard its amyloid aggregation. Huard DJE; Jonke AP; Torres MP; Lieberman RL Sci Rep; 2019 Sep; 9(1):12769. PubMed ID: 31484937 [TBL] [Abstract][Full Text] [Related]
11. Progress toward development of a proteostasis drug for myocilin-associated glaucoma. Huard DJ; Lieberman RL Future Med Chem; 2018 Jun; 10(12):1391-1393. PubMed ID: 29788763 [No Abstract] [Full Text] [Related]
12. GRP94/gp96 in Cancer: Biology, Structure, Immunology, and Drug Development. Wu BX; Hong F; Zhang Y; Ansa-Addo E; Li Z Adv Cancer Res; 2016; 129():165-90. PubMed ID: 26916005 [TBL] [Abstract][Full Text] [Related]
13. Biological Evaluation of 5'-( Tosh DK; Brackett CM; Jung YH; Gao ZG; Banerjee M; Blagg BSJ; Jacobson KA ACS Med Chem Lett; 2021 Mar; 12(3):373-379. PubMed ID: 33738064 [TBL] [Abstract][Full Text] [Related]
14. Investigation of the site 2 pocket of Grp94 with KUNG65 benzamide derivatives. Pugh K; Xu H; Blagg BSJ Bioorg Med Chem Lett; 2024 Oct; 111():129893. PubMed ID: 39043265 [TBL] [Abstract][Full Text] [Related]
15. Structure-activity relationship in a purine-scaffold compound series with selectivity for the endoplasmic reticulum Hsp90 paralog Grp94. Patel HJ; Patel PD; Ochiana SO; Yan P; Sun W; Patel MR; Shah SK; Tramentozzi E; Brooks J; Bolaender A; Shrestha L; Stephani R; Finotti P; Leifer C; Li Z; Gewirth DT; Taldone T; Chiosis G J Med Chem; 2015 May; 58(9):3922-43. PubMed ID: 25901531 [TBL] [Abstract][Full Text] [Related]
16. Structure Based Design of a Grp94-Selective Inhibitor: Exploiting a Key Residue in Grp94 To Optimize Paralog-Selective Binding. Que NLS; Crowley VM; Duerfeldt AS; Zhao J; Kent CN; Blagg BSJ; Gewirth DT J Med Chem; 2018 Apr; 61(7):2793-2805. PubMed ID: 29528635 [TBL] [Abstract][Full Text] [Related]
17. Different poses for ligand and chaperone in inhibitor-bound Hsp90 and GRP94: implications for paralog-specific drug design. Immormino RM; Metzger LE; Reardon PN; Dollins DE; Blagg BS; Gewirth DT J Mol Biol; 2009 May; 388(5):1033-42. PubMed ID: 19361515 [TBL] [Abstract][Full Text] [Related]
18. NECA derivatives exploit the paralog-specific properties of the site 3 side pocket of Grp94, the endoplasmic reticulum Hsp90. Huck JD; Que NLS; Immormino RM; Shrestha L; Taldone T; Chiosis G; Gewirth DT J Biol Chem; 2019 Nov; 294(44):16010-16019. PubMed ID: 31501246 [TBL] [Abstract][Full Text] [Related]
19. Endoplasmic Reticulum-resident Heat Shock Protein 90 (HSP90) Isoform Glucose-regulated Protein 94 (GRP94) Regulates Cell Polarity and Cancer Cell Migration by Affecting Intracellular Transport. Ghosh S; Shinogle HE; Galeva NA; Dobrowsky RT; Blagg BS J Biol Chem; 2016 Apr; 291(16):8309-23. PubMed ID: 26872972 [TBL] [Abstract][Full Text] [Related]
20. Design, synthesis, and evaluation of a radicicol and geldanamycin chimera, radamide. Clevenger RC; Blagg BS Org Lett; 2004 Nov; 6(24):4459-62. PubMed ID: 15548050 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]